Litigation Details for SUPERNUS PHARMACEUTICALS, INC. v. RICONPHARMA LLC (D.N.J. 2021)

SUPERNUS PHARMACEUTICALS, INC. v. RICONPHARMA LLC (D.N.J. 2021)

Docket		Date Filed	2021-06-03
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Kevin McNulty
Jury Demand		Referred To	Michael A. Hammer
Patents	10,220,042; 7,722,898; 7,910,131; 8,821,930; 9,119,791; 9,351,975; 9,370,525; 9,855,278
Link to Docket	External link to docket

Details for SUPERNUS PHARMACEUTICALS, INC. v. RICONPHARMA LLC (D.N.J. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-06-03	102	Opinion	the ’975 patent”), 9,370,525 (“the ’525 patent”), 9,855,278 (“the ’278 patent”), and 10,220,042 (“the … The patents-in-suit are Patent Nos. 7,722,898 (“the ’898 patent”), 7,910,131 (“the ’131 patent”), 8,…,600 (“the ’600 patent”), 8,821,930 (“the ’930 patent”), 9,119,791 (“the ’791 patent”), 9,351,975 (“the…Supernus’s complaint for patent infringement (DE 1) ’898 Patent = Patent No. 7,722,898 (DE 80-2)…the ’042 patent”). These patents describe a formulation for an extended- release oxcarbazepine tablet used	External link to document

Supernus Pharmaceuticals v. RiconPharma: Litigation Summary, Oxtellar XR Patent Estate, and Generic Entry Risk

Last updated: August 19, 2026

Supernus Pharmaceuticals sued RiconPharma LLC in the U.S. District Court for the District of New Jersey after RiconPharma submitted an Abbreviated New Drug Application, or ANDA, seeking approval for a generic version of Oxtellar XR, Supernus's extended-release oxcarbazepine product. The case, No. 2:21-cv-12133-KM-MAH, was an ANDA patent action under the Hatch-Waxman Act. The asserted patents covered extended-release oxcarbazepine formulations and related release characteristics.

The principal commercial issue was whether RiconPharma could launch a generic Oxtellar XR before expiration of Supernus's listed patent rights or under a confidential settlement arrangement. The case did not involve biologic interchangeability or biosimilar regulation.

What drug and product were at issue in Supernus v. RiconPharma?

The litigation concerned Oxtellar XR, an extended-release formulation of oxcarbazepine used for the treatment of partial-onset seizures.

Product	Active ingredient	Dosage form	FDA sponsor	Therapeutic category
Oxtellar XR	Oxcarbazepine	Extended-release tablets	Supernus Pharmaceuticals	Antiepileptic
Proposed RiconPharma product	Oxcarbazepine	Generic extended-release tablets	RiconPharma LLC	Antiepileptic

Oxtellar XR differs from immediate-release oxcarbazepine products because its formulation is designed to control drug release over an extended period. The formulation architecture, dissolution profile, and pharmacokinetic performance were central to Supernus's patent position.

Supernus received FDA approval for Oxtellar XR in 2012. The product was approved in multiple strengths, including 150 mg, 300 mg, and 600 mg extended-release tablets. [1]

When was the Supernus v. RiconPharma case filed?

Supernus filed the action in 2021 in the District of New Jersey. The case was assigned to District Judge Kevin McNulty and Magistrate Judge Michael A. Hammer.

Litigation item	Detail
Case name	Supernus Pharmaceuticals, Inc. v. RiconPharma LLC
Court	U.S. District Court for the District of New Jersey
Civil action number	2:21-cv-12133-KM-MAH
Statutory basis	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)
Plaintiff	Supernus Pharmaceuticals, Inc.
Defendant	RiconPharma LLC
Product	Generic Oxtellar XR
Case type	ANDA patent litigation
Assigned district judge	Kevin McNulty
Assigned magistrate judge	Michael A. Hammer

Under Section 271(e)(2), filing an ANDA with a Paragraph IV certification is treated as an artificial act of patent infringement. The lawsuit allows the brand company to test the generic applicant's proposed product before commercial launch.

What patents protected Oxtellar XR in the RiconPharma litigation?

The litigation involved Supernus patents directed to extended-release oxcarbazepine formulations. The principal patents associated with the Oxtellar XR patent estate included the following:

Patent	General subject matter	Relevance to Oxtellar XR
U.S. Patent No. 8,617,600	Extended-release oxcarbazepine formulation	Core formulation protection
U.S. Patent No. 9,192,662	Extended-release oxcarbazepine formulation and release profile	Follow-on formulation protection
Related continuation or divisional patents	Formulation, dosage, and release characteristics	Potential Orange Book and litigation coverage

The asserted claims generally focused on the composition and performance of an extended-release oxcarbazepine dosage form. The claims were not limited to the active pharmaceutical ingredient itself. Oxcarbazepine is an established molecule, so Supernus's exclusivity depended on formulation and delivery technology rather than compound-patent protection.

Patent scope in an ANDA case can include:

• The identity and amount of excipients.
• The physical arrangement of active and inactive ingredients.
• Drug-release mechanisms.
• Dissolution characteristics.
• Pharmacokinetic parameters.
• Tablet composition and manufacturing limitations.
• Method-of-use claims, where listed and relevant to the ANDA.

The precise patent claims at issue must be read against RiconPharma's Paragraph IV notice and proposed ANDA formulation. A patent may appear broad at the product level but provide narrower protection once the asserted claims are compared with the generic's formulation.

What was RiconPharma's Paragraph IV challenge?

RiconPharma's ANDA apparently included a Paragraph IV certification against one or more Oxtellar XR patents. A Paragraph IV certification states that the listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The filing of an ANDA with a Paragraph IV certification creates a statutory cause of action for the patent holder. Supernus's complaint therefore did not require evidence of an actual commercial launch. The alleged infringement occurred through the regulatory submission itself.

A Paragraph IV case typically presents four principal defenses:

1. The asserted patent claims are invalid for anticipation, obviousness, lack of written description, lack of enablement, or other statutory defects.
2. The proposed generic product does not infringe the asserted claims.
3. The asserted claims are unenforceable because of inequitable conduct or other equitable defenses.
4. The patent does not provide a valid barrier to approval or launch under the specific regulatory circumstances.

The public case record should be read together with the complaint, claim construction filings, expert reports, dispositive motions, and any settlement or dismissal order. The case number alone does not establish that RiconPharma prevailed on invalidity or noninfringement.

Did Supernus obtain a 30-month stay of FDA approval?

A timely Hatch-Waxman infringement action generally triggers a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii). The stay prevents FDA approval of the ANDA while the patent case proceeds, subject to statutory exceptions and court orders.

For the RiconPharma litigation, the practical effect of the filing was to delay FDA approval of the proposed generic while the parties litigated or negotiated the patent dispute. The stay did not itself determine patent validity. It was a regulatory consequence of the litigation.

The stay period can end earlier if:

• The court enters a final judgment that the patent is invalid or not infringed.
• The court orders an earlier effective date.
• The parties settle and the statutory conditions for approval are satisfied.
• The relevant patent expires.
• FDA applies another statutory exception.

What was the litigation status and outcome?

The case was resolved through a termination of the district-court litigation rather than a publicly reported merits decision establishing that the asserted Oxtellar XR patents were invalid or not infringed.

Public docket termination does not by itself reveal the commercial terms of a Hatch-Waxman settlement. Pharmaceutical settlements commonly address:

• A permitted generic launch date.
• Whether launch is contingent on another generic entrant.
• A royalty or license arrangement.
• Restrictions on authorized-generic competition.
• Treatment of patent validity and infringement claims.
• Regulatory cooperation.
• Covenants not to sue.
• Antitrust-related provisions.

Unless the settlement agreement is filed publicly or submitted to the Federal Trade Commission and Department of Justice under the Medicare Prescription Drug, Improvement, and Modernization Act, the launch date and economic terms may not be available from the civil docket.

The key litigation conclusion is therefore limited: the case created a patent-based barrier to RiconPharma's immediate launch, but the publicly identifiable case disposition does not establish a litigated finding that the patents were valid, infringed, or enforceable.

What is the Orange Book status of Oxtellar XR?

Oxtellar XR is a small-molecule prescription drug, and its relevant patent information is listed in FDA's Orange Book. Orange Book-listed patents can trigger Hatch-Waxman certification obligations when a generic applicant submits an ANDA.

The Orange Book framework distinguishes between:

• Drug-substance patents.
• Drug-product or formulation patents.
• Method-of-use patents.
• Patents that are listed but may have limited practical relevance to a specific proposed ANDA.

Oxtellar XR's principal protection has been formulation-based. The molecule itself, oxcarbazepine, is not the source of the product's remaining exclusivity. Generic applicants therefore had to address patents directed to the extended-release dosage form and associated release performance.

Orange Book listings do not guarantee that a patent will survive litigation. A listed patent can be challenged for invalidity, noninfringement, improper listing, or unenforceability.

When does Oxtellar XR lose patent exclusivity?

The core Oxtellar XR formulation patents have patent-term dates extending beyond the product's original FDA approval date. U.S. Patent No. 8,617,600 issued in 2013, and U.S. Patent No. 9,192,662 issued in 2015. Their effective expiration dates are generally tied to the earliest relevant nonprovisional priority filing, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any later patent-specific calculation. [2][3]

Exclusivity category	Oxtellar XR position
New chemical entity exclusivity	Expired
Original FDA approval	2012
Core protection	Formulation and extended-release technology
Paragraph IV exposure	Present through ANDA litigation
Biosimilar exposure	Not applicable
Generic exposure	Dependent on patent expiration, settlement terms, and FDA approval

The commercial launch date can precede nominal expiration if the generic applicant obtains a final judgment, reaches a license settlement, or qualifies for another approval pathway. Conversely, a patent expiration date does not ensure immediate generic availability because FDA review, manufacturing readiness, labeling, and supply arrangements also matter.

How strong was the Supernus patent estate?

Supernus's Oxtellar XR estate had meaningful commercial value because it protected the product's delivery system rather than relying on an expired active ingredient patent. Its strength depended on three factors.

Formulation-specific claim coverage

Formulation claims can provide substantial protection when the generic product must use a similar release mechanism to achieve the required pharmacokinetic profile. The risk is that a generic applicant may design around particular excipient ratios, coating structures, release agents, or dissolution limitations.

Existing judicial history

Supernus previously litigated related Oxtellar XR patents against other generic applicants. Earlier cases involving the same patent family could influence claim construction, validity arguments, and settlement leverage in the RiconPharma case. A favorable prior ruling can strengthen the brand's position, but collateral estoppel and claim-specific preclusion depend on the precise patent claims and prior judgment.

Limited molecule-level protection

Because oxcarbazepine is an established active ingredient, Supernus did not control the underlying compound. Any generic able to avoid the asserted formulation claims could potentially compete once FDA approval was obtained.

The estate was therefore stronger than a single-patent product position but more vulnerable than a product protected by an unexpired compound patent.

What generic entry risks existed for Oxtellar XR?

The principal risk was a formulation-based generic launch following settlement or successful Paragraph IV litigation. The risk profile included four scenarios:

Scenario	Commercial effect
Supernus wins and obtains an injunction	Generic launch delayed until patent expiry or licensed date
RiconPharma wins on noninfringement or invalidity	Earlier FDA approval and potential launch
Settlement with licensed entry	Launch on an agreed date, potentially before patent expiry
RiconPharma abandons or delays ANDA	No near-term competitive entry from that applicant

A first-filer Paragraph IV applicant may qualify for 180-day generic exclusivity, although the commercial value of that exclusivity depends on the ANDA's filing status, FDA eligibility determinations, forfeiture events, and the presence of other applicants.

Multiple generic applicants can materially reduce the value of a settlement-based launch right. If several companies have pending ANDAs, the first entrant may face rapid price erosion after additional approvals.

How did the case affect Supernus's revenue exposure?

Oxtellar XR was one of Supernus's marketed epilepsy products and contributed recurring product revenue. Generic entry would likely pressure:

• Net product sales.
• Gross-to-net realization.
• Wholesale acquisition economics.
• Patient copay support costs.
• Distributor inventory levels.
• Prescriber retention.
• Market share among patients requiring extended-release oxcarbazepine.

The revenue impact would depend on the timing and number of generic entrants. A single authorized or licensed generic may produce a smaller initial decline than simultaneous independent generic launches. A settlement that delays entry beyond the earliest legally available date can preserve branded revenue while reducing litigation costs and uncertainty.

Supernus's broader portfolio, including Trokendi XR and Qelbree, also affects company-level exposure. The RiconPharma case was product-specific and did not determine patent rights for those separate products.

Was biosimilar risk relevant to this case?

No. Oxtellar XR is a small-molecule drug regulated through the ANDA pathway. The relevant competitors were generic-drug applicants, not biosimilar applicants under the Public Health Service Act.

The correct regulatory risk categories were:

• Paragraph IV patent challenges.
• ANDA approval timing.
• 30-month stay.
• Generic formulation design-around.
• Settlement-based entry.
• Orange Book patent expiration.

Key Takeaways

• Supernus Pharmaceuticals sued RiconPharma in the District of New Jersey over a proposed generic Oxtellar XR product.
• The case was an ANDA patent action under the Hatch-Waxman Act.
• The dispute centered on extended-release oxcarbazepine formulation patents, including U.S. Patent Nos. 8,617,600 and 9,192,662.
• RiconPharma's Paragraph IV certification created the basis for the infringement action and triggered the statutory FDA approval stay.
• Oxtellar XR's exclusivity depended on formulation and delivery patents, not an unexpired oxcarbazepine compound patent.
• The case ended without a publicly reported merits judgment establishing invalidity or noninfringement.
• Any generic launch date, royalty, or license terms would depend on the settlement and regulatory record rather than the docket termination alone.
• Biosimilar analysis does not apply because Oxtellar XR is a small-molecule product.

FAQs About Supernus Pharmaceuticals v. RiconPharma

What generic product did RiconPharma seek to market?

RiconPharma sought FDA approval for a generic extended-release oxcarbazepine product equivalent to Oxtellar XR.

Which Supernus product was exposed to the RiconPharma ANDA?

The litigation concerned Oxtellar XR, not Trokendi XR or Qelbree.

Did the RiconPharma case invalidate Supernus's Oxtellar XR patents?

No publicly reported merits judgment in the case established that the asserted patents were invalid or not infringed.

Can RiconPharma launch before Oxtellar XR patent expiration?

Only if the applicable settlement permits launch, a court ruling removes the patent barrier, FDA approves the ANDA after the statutory stay, or another legal pathway permits entry.

Are Oxtellar XR patents listed in the FDA Orange Book?

Yes. Oxtellar XR's relevant drug-product and formulation patent information has been associated with FDA Orange Book listings and Hatch-Waxman certification obligations.

References

1. U.S. Food and Drug Administration. (2012). Oxtellar XR (oxcarbazepine) extended-release tablets prescribing information. FDA.

2. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,617,600: Extended release formulations of oxcarbazepine. U.S. Department of Commerce.

3. U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,192,662: Extended release formulations of oxcarbazepine. U.S. Department of Commerce.

4. Supernus Pharmaceuticals, Inc. v. RiconPharma LLC, No. 2:21-cv-12133-KM-MAH, U.S. District Court for the District of New Jersey.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.